Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: Adult subjects aged greater than or equal to 18 and less than or equal to 60 years and elderly subjects greater than 61 years of age.

Trial Profile

Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: Adult subjects aged greater than or equal to 18 and less than or equal to 60 years and elderly subjects greater than 61 years of age.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 14 Sep 2007 Status changed from in progress to completed.
    • 29 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top